For multinational pharmaceutical companies, CDMOs, biotech innovators, and API manufacturers operating across multiple jurisdictions, regulatory alignment is now a strategic priority
The Nitrosamine (NA) issue, often termed the "Saga," has been a focal point of attention for both the pharmaceutical sector and regulatory entities over the past half-decade...
